Eloxx Pharmaceuticals (ELOX) & Its Peers Financial Contrast

Eloxx Pharmaceuticals (NASDAQ:ELOX) is one of 902 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Eloxx Pharmaceuticals to similar companies based on the strength of its institutional ownership, earnings, analyst recommendations, valuation, risk, dividends and profitability.

Profitability

This table compares Eloxx Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Eloxx Pharmaceuticals Competitors	-2,319.38%	-223.57%	-16.98%

Analyst Ratings

This is a summary of recent ratings and target prices for Eloxx Pharmaceuticals and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1	0	3	1	2.80
Eloxx Pharmaceuticals Competitors	7596	13657	25475	1001	2.42

Eloxx Pharmaceuticals currently has a consensus price target of $38.33, indicating a potential upside of 110.05%. As a group, “Pharmaceuticals” companies have a potential upside of 27.07%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Eloxx Pharmaceuticals is more favorable than its rivals.

Earnings & Valuation

This table compares Eloxx Pharmaceuticals and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36 million	-$5.99 million	-11.85
Eloxx Pharmaceuticals Competitors	$17.90 billion	$3.15 billion	547.41

Eloxx Pharmaceuticals’ rivals have higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Eloxx Pharmaceuticals has a beta of -1862.26, meaning that its share price is 186,326% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals’ rivals have a beta of -3.17, meaning that their average share price is 417% less volatile than the S&P 500.

Institutional & Insider Ownership

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 14.3% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Eloxx Pharmaceuticals beats its rivals on 8 of the 13 factors compared.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.